Montelukast and Disulfiram were sel﻿ected as potentially clinically applicable drug﻿s and tested to reduce serum unconjugated bilirubin (UCB) levels in the Ugt1a1-deficient rat, a model for chronic unconjugated hyperbilirubinemia. Here, UGT1A1 is linked to Hyperbilirubinemia.